AnaBios CEO and leadership

Andre Ghetti, PhD, is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization. Prior to joining AVIVA Biosciences Dr. Ghetti was involved in drug discovery programs at Aurora Biosciences first, and later at Vertex Pharmaceuticals. Dr. Ghetti received his Ph.D. in Molecular and Cellular Physiology from the University of Verona (Italy) and completed his postdoctoral training at the California Institute of Technology. Between 1996 and 2001, worked as a staff scientist at the Salk Institute, in La Jolla, California. During the last several years, he has focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate of successful drug discovery and development.

Paul E. Miller, PhD, is a Founding Partner and the Chief Business & Corporate Development Officer of AnaBios. He also founded Consulting Life Sciences, a biotechnology consulting and brokerage firm established in 2007. Dr. Miller holds a BSc in Biochemistry from Dartmouth College (1979, Hanover, NH, USA) and a PhD in Physiology from McGill University Faculty of Medicine (1989, Montreal, Canada). His scientific career has spanned over 30 years with publications in prestigious journals such as Science and American Journal of Physiology. Over the years, Dr. Miller has conducted research across several areas of human physiology including differentiation and cancer, feto-maternal immunology, protein secretion pathways, intestinal motility and functional genomics. With an extensive parallel business experience in the cultural artistic industry from 1986 to 2001, Dr. Miller has since combined his scientific expertise and his business acumen for the past 17 years in the biopharmaceutical industry. He has also successfully developed and marketed several innovative projects and services for preclinical CROs aimed at increasing the efficiency of the drug discovery, safety and development processes.

As Chief Commercial Officer (CCO) of AnaBios, Dr. Chris Mathes provides leadership in business development activities and contributes to the strategic direction of the company. Previously, Mathes acted as the CCO of the early drug discovery company, Icagen. Prior to Icagen, Dr. Mathes led North American business development efforts for Discovery services at Charles River Laboratories. Dr. Mathes was CCO at ChanTest (acquired by Charles River in 2014), a market leader in ion channel drug discovery and associated in vitro safety testing. Prior to ChanTest, he established and managed all aspects of the U.S. subsidiary of Sophion Bioscience A/S (Denmark) as Vice President & General Manager. Mathes has over 25 years of experience in the ion channel field and contributed to the early development and marketing strategy of automated patch clamp systems. He earned a B.S. in Biology from Stanford University (with departmental honors). He received his Ph.D. in Neuroscience from the University of California, Los Angeles in 1995. In 2009, Mathes earned an Executive M.B.A. degree from Rutgers University. He established Candidate Biopharma Advisors in January 2018.

Paul E. Miller, PhD, is a Founding Partner and the Chief Business & Corporate Development Officer of AnaBios. He also founded Consulting Life Sciences, a biotechnology consulting and brokerage firm established in 2007. Dr. Miller holds a BSc in Biochemistry from Dartmouth College (1979, Hanover, NH, USA) and a PhD in Physiology from McGill University Faculty of Medicine (1989, Montreal, Canada). His scientific career has spanned over 30 years with publications in prestigious journals such as Science and American Journal of Physiology. Over the years, Dr. Miller has conducted research across several areas of human physiology including differentiation and cancer, feto-maternal immunology, protein secretion pathways, intestinal motility and functional genomics. With an extensive parallel business experience in the cultural artistic industry from 1986 to 2001, Dr. Miller has since combined his scientific expertise and his business acumen for the past 17 years in the biopharmaceutical industry. He has also successfully developed and marketed several innovative projects and services for preclinical CROs aimed at increasing the efficiency of the drug discovery, safety and development processes.

Andre Ghetti, PhD, is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization. Prior to joining AVIVA Biosciences Dr. Ghetti was involved in drug discovery programs at Aurora Biosciences first, and later at Vertex Pharmaceuticals. Dr. Ghetti received his Ph.D. in Molecular and Cellular Physiology from the University of Verona (Italy) and completed his postdoctoral training at the California Institute of Technology. Between 1996 and 2001, worked as a staff scientist at the Salk Institute, in La Jolla, California. During the last several years, he has focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate of successful drug discovery and development.